1362317-67-6

Upstream product

• 186046-91-3 methyl (cytosine-1-yl)acetate 
• 168263-86-3 N⁴-benzoylcytosine-1-acetic acid 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 1362317-66-5 C₄₉H₅₀N₁₀O₁₀ 
• 124482-92-4 2-cyanoethyl-N,N-(diisopropylamino)chlorophosphine 
• 1362317-65-4 C₅₅H₆₄N₁₀O₁₀Si 
• 1362317-64-3 N-(1-(2-((2-azidoethyl)(2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide 
• 1362317-63-2 C₂₃H₃₃N₇O₄Si 
• 1362317-68-7 C₁₇H₁₉N₇O₄ 
• 1313022-54-6 N-(2-(tert-butyldimethylsilyloxy)ethyl)-uracil-1-yl-N-(prop-2-yn-1-yl)acetamide 
• 924906-60-5 N-(prop-2-ynyl)-N-[2-(tert-butyldimethylsilanyloxy)ethyl]amine 

Relevant academic research and scientific papers

Efficient synthesis and cell-based silencing activity of siRNAS that contain triazole backbone linkages

An efficient synthesis of siRNAs modified at the backbone with a triazole functionality is reported. Through the use of 4,4×-dimethoxytrityl (DMT) phosphoramidite chemistry, triazole backbone dimmers were site-specifically incorporated throughout various siRNAs targeting both firefly luciferase and glyceraldehyde- 3-phosphate dehydrogenase (GAPDH) gene transcripts as representatives of an exogenous and endogenous gene, respectively. Following the successful silencing of the firefly luciferase reporter gene, triazole-modified siRNAs were also found to be capable of silencing GAPDH in a dose-dependent manner. Backbone modifications approaching the 3×-end on the sense strand were tolerated without compromising siRNA potency. This study highlights the compatibility of triazole-modified siRNAs within the RNAi pathway, and the modification's potential to impart favorable properties to siRNAs designed to target other endogenous genes.